Citations

Clear

6273 citation(s) found for "To, Andrew".

Abstract 4123956: Upgrade to Implantable Cardioverter-Defibrillator in Patients Diagnosed with Cardiac Sarcoidosis after Permanent Pacemaker Implantation for High-Grade Atrioventricular Block
Austin, Brett C , Rosenbaum, Andrew , Giudicessi, John R. , Bois, John P. , Bratcher, Melanie, Deshmukh, Abhishek , Siontis, Konstantinos C. , AbouEzzeddine, Omar F. , Kapa, Suraj

Mayo Clinic

Circulation | November 13, 2024 | Volume: 150 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.150.suppl_1.4123956 Get It

Introduction: Unexplained high-grade AV block (AVB) in patients age <65 years is among the salient features of cardiac sarcoidosis (CS). Guidelines recommend that CS patients with high-grade AVB should receive an implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy-defibrillator (CRT-D) rather than a permanent pacemaker (PPM). However, in clinical practice, CS may be recognized after PPM implantation for high-grade AVB. Aims: To evaluate the characteristics and outcomes of patients diagnosed with CS after PPM implantation for high-grade AVB and assess the decision-making and rationale for upgrade to ICD/CRT-D. Methods: Retrospective review of the Mayo Clinic Sarcoid Registry (n=848) was performed to identify all patients for which a PPM was implanted for high-grade AVB prior to the diagnosis of CS. Baseline clinical and imaging characteristics were collected during index evaluation at our institution. Decision-making for ICD upgrade, lead management strategy, immunosuppression initiation, and outcomes were assessed. Results: Overall, 29 of 848 (3.4%) of CS patients (62% probable/definite CS; 77% male; median (IQR) age 56 (48-61) years; and median (IQR) LVEF 58% (50-62) received a PPM for high-grade AVB prior to a CS diagnosis. Median (IQR) interval between PPM implant and index evaluation was 10 (3-23) months. Eight of 29 patients underwent upgrade to ICD (n=4) or CRT-D (n=4). Among them, the pacing lead was extracted in 4. All patients were upgraded for primary prevention of sudden cardiac death (SCD), with 3 of them also having LVEF<50% requiring upgrade to CRT-D. Twenty-two (79%) patients in the total cohort were treated with immunosuppression. During median (IQR) follow-up 37 months (11-74), 1 patient in the upgrade group had sustained VT appropriately treated with anti-tachycardia pacing. No events were documented among patients in the non-upgrade group. At last follow-up, 6 (75%) patients in the upgrade group and 12 (57%) in the non-upgrade group were pacemaker dependent. Median LVEF change was 0% in patients who underwent upgrade to CRT-D and –0.2% in those who underwent upgrade to ICD or no upgrade. Conclusions: In this cohort of patients diagnosed with CS several months after a PPM had been implanted for high-grade AVB, incident VT/VF was infrequent with contemporary CS management. In the absence of other SCD risk factors, CS patients who received a PPM for high-grade AVB prior to their CS diagnosis may not require ICD upgrade.
NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024
Thompson, John A. , Schneider, Bryan J. , Brahmer, Julie R. , Zaid, Mohammad Abu , Achufusi, Amaka, Armand, Philippe , Bermas, Bonnie L. , Braaten, Tawnie , Chokshi, Saurin , Crees, Zachary , Davies, Marianne, Deng, Changchun , Gesthalter, Yaron , Jallouk, Andrew , Khalil, Maya, Marr, Alissa , McGettigan, Suzanne , Medina, Theresa , Mohindra, Nisha , Patel, Sandip Pravin , Prosek, Jason, Reddy, Sunil , Reid, Pankti , Ryder, Mabel , Shofer, Scott , Sosman, Jeffrey A. , Zucker, Stephen D. , Lyons, Megan , Hang, Lisa, Ryder, Mabel , Berkenstock, Meghan , Bermas, Bonnie , Budde, Lihua E. , Jain, Michael D. , Jain, Prantesh , Kaffenberger, B , Lechner, Melissa G , Li, Tianhong , McPherson, Jordan P. , Medina, Theresa Michelle , Olszanski, Anthony J. , Oluwole, Olalekan O. , Ryan, John, Salman, Huda , Santomasso, Bianca , Wang, Yinghong , Zaha, Vlad G , Awotiwon, Ajibola

Mayo Clinic

Journal of the National Comprehensive Cancer Network | November 13, 2024 | Volume: 22 | Issue: 9 | Pages: 582-592

10.6004/jnccn.2024.0057 | PMID 39536465 Get It

The NCCN Guidelines for the Management of Immunotherapy-Related Toxicities are intended to provide oncology practitioners with guidance on how to manage the wide-ranging and potentially fatal toxicities that may occur with cancer immunotherapy. The guidelines address immune-related adverse events related to immune checkpoint inhibitors, CAR T-cell therapies, and lymphocyte engagers (which include T-cell–engaging bispecific antibodies). These NCCN Guidelines Insights highlight recent guideline updates pertaining to the management of emerging toxicities related to cancer immunotherapy.
TMOD-18. FUNCTIONAL DISSECTION OF RECURRENT COPY-NUMBER-ALTERATIONS INFORMS MECHANISMS OF LOW-GRADE-GLIOMA PROGRESSION
Haider, Shahan , Kollmeyer, Thomas M. , Tsai, Ricky , Chiu, Cynthia H. , Elia, Andrew , Jenkins, Robert P. , Kollmeyer, Thomas , Drucker, Kristen , Al‐Zahrani, Khalid N. , Jenkins, Robert, Schramek, Daniel

Mayo Clinic

Neuro-Oncology | November 11, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii322-viii323

10.1093/neuonc/noae165.1282 Get It

Abstract Low-grade gliomas (LGG) are slowly growing brain cancers that ultimately undergo a malignant progression to lethal secondary glioblastomas with a dismal prognosis. Despite intensive research, very little progress has been made in our understanding of this transformation. Hence, outside of known alternations in well-characterized driver genes CDKN2A, PTEN and PDGFRA, genetic drivers that underlie LGG transformation are largely unknown. Contrary to other types of cancer, LGGs exhibit very few driver mutations (30-40 mutations) as they progress. Interestingly, LGGs also exhibit a highly prevalent and heterogenous pattern of copy-number-alterations (CNAs) suggesting that they might be driven by changes in gene dosages that result from widespread chromosomal instability observed within these tumors. Through analysis of the human Mayo Clinic and TCGA LGG datasets (~1500 patients), we have identified eleven highly recurrent CNAs affecting LGG patients, many of which correlate with patient survival. We hypothesized that these CNAs contain driver genes that confer a growth advantage resulting in the highly recurrent CNA pattern and prognostic associations. To investigate the tumor suppressive potential of the ~1800 genes located in recurrently deleted regions and the oncogenic potential of the ~1200 genes located in recurrently amplified regions, our lab developed a novel in vivo ‘CRISPR-Knock Out and Activation Linked Assay’ (CRISPR-KOALA). Stereotaxic delivery of arm-level CNA lentiviral gRNA libraries targeting the mouse orthologs of genes in CNAs into the brain of our animal model (rs557mut;IDHmut;P53KO;AtrxKO;Cas9GFP: Yanchus et. al Science 2022) resulted in rapid formation of tumors compared to animals injected with control libraries. Deconvoluting the screen revealed enrichment of immune modulators such as Them6 as well as a modulator of NMDA receptors (Grina) implicating immune system and glutamate dysregulation in LGG malignant transformation. Taken together, our study provides insights into mechanisms underlying LGG progression which may serve to inform intervention strategies for this lethal disease.
Abstract 4136926: Premature Ventricular Complexes and Nonsustained Ventricular Tachycardia in Cardiac Sarcoidosis
Melo, Jose de, Debertin, Julia , Rosenbaum, Andrew , Bois, John P. , Deshmukh, Abhishek , Siontis, Konstantinos C. , Melo, Jose F de , Castrichini, Matteo , AbouEzzeddine, Omar F. , Kapa, Suraj , Asirvatham, Samuel J.

Mayo Clinic

Circulation | November 11, 2024 | Volume: 150 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.150.suppl_1.4136926 Get It

Introduction: The prevalence and prognostic significance of PVC and NSVT in cardiac sarcoidosis (CS), especially in patients with normal or mildly decreased LV function, are not well known and were investigated in the current study. Methods: We included 192 patients with definite and probable CS with LVEF>35%, no prior history of VT/VF or sudden cardiac death, who underwent up to 48 hours of Holter monitoring. They were followed retrospectively for the composite endpoint of sustained VT/VF, advanced heart failure therapy, and all-cause mortality. We performed multivariable analysis for the association of PVC burden and NSVT with the composite endpoint. Covariates were considered if they were present in at least 95% of the study sample and were significantly associated with the composite endpoint in univariable analysis. Results: The median PVC burden in the overall population was 0.3% (IQR 0.02-2.5%) and 36 (18.8%) patients had a PVC burden ≥5%. Sixty-two (32.3%) patients had NSVT detected during monitoring. The PVC burden and prevalence of NSVT in patient subgroups are shown in Figures 1 and 2. A total of 33 (17.2%) patients experienced one of the composite endpoints at a median follow-up of 3 years. In the multivariable analysis (Figure 3), PVC burden ≥5% versus <5% (HR 3.96 [1.19, 5.97], p-value <0.01) and presence of NSVT (HR 4.55 [2.09, 9.94], p-value <0.01) were associated with the composite outcome. Conclusion: Our results suggest that a high PVC burden and the presence of NSVT carry isolated prognostic value in CS. In addition, ventricular ectopy does not appear to be an indicator of disease activity based on abnormal uptake on PET scan.
Nomenclature for human and animal fungal pathogens and diseases: a proposal for standardized terminology
Walsh, Thomas J. , Ahmed, Sarah , Alastruey‐Izquierdo, Ana , Arendrup, Maiken Cavling , Borman, Andrew M. , Colgrove, Robert C. , Cornely, Oliver A. , Filkins, Laura , Groll, Andreas H. , Haase, Gerhard , Hubka, Vít , Kwon-Chung, June , Song, Yinggai , Vilela, Rachel, Vitale, Roxana G. , Wengenack, Nancy L. , de Hoog, Sybren , Walsh, Thomas J , Alastruey-Izquierdo, A , Arendrup, Maiken Cavling , Borman, Andrew , Filkins, Laura , Gené, Josepa , Groll, Andreas H , Hoenigl, Martin , Kidd, Sarah E , Kus, Julianne V , Kwon-Chung, Kyung J , Lockhart, Shawn R. , Meis, Jacques F , Mendoza, Leonel , Nguyen, M Hong , Vitale, Roxana G , Wengenack, Nancy L , White, Lewis , Zhang, Sean X , Cornely, Oliver A , Ahmed, Sarah A , Chen, Wen , Chowdhary, Anuradha , Denning, David W. , Dufresne, Philippe J. , Gangneux, Jean‐Pierre , Guillot, Jacques , Halliday, Catriona , Hawksworth, David L. , Hay, Roderick J. , Hoenigl, Martin , Jagielski, Tomasz , Kandemir, Hazal , Kidd, Sarah , Kus, Julianne V. , Kwon‐Chung, June , Meyer, Wieland , Song, Yinggai , Sorrell, Tania Christine , Stielow, J. Benjamin , Ostrosky‐Zeichner, Luis , Zhang, Sean X.

Mayo Clinic

Journal of Clinical Microbiology | November 11, 2024 | Volume: 62 | Issue: 12 | Pages: No page available

10.1128/jcm.00937-24 | PMID 39526838 Get It

ABSTRACT Medically important pathogenic fungi invade vertebrate tissue and are considered primary when part of their nature life cycle is associated with an animal host and are usually able to infect immunocompetent hosts. Opportunistic fungal pathogens complete their life cycle in environmental habitats or occur as commensals within or on the vertebrate body, but under certain conditions can thrive upon infecting humans. The extent of host damage in opportunistic infections largely depends on the portal and modality of entry as well as on the host’s immune and metabolic status. Diseases caused by primary pathogens and common opportunists, causing the top approximately 80% of fungal diseases [D. W. Denning, Lancet Infect Dis, 24:e428–e438, 2024, https://doi.org/10.1016/S1473-3099(23)00692-8 ], tend to follow a predictive pattern, while those by occasional opportunists are more variable. For this reason, it is recommended that diseases caused by primary pathogens and the common opportunists are named after the etiologic agent, for example, histoplasmosis and aspergillosis, while this should not be done for occasional opportunists that should be named as [causative fungus] [clinical syndrome], for example, Alternaria alternata cutaneous infection. The addition of a descriptor that identifies the location or clinical type of infection is required, as the general name alone may cover widely different clinical syndromes, for example, “rhinocerebral mucormycosis.” A list of major recommended human and animal disease entities (nomenclature) is provided in alignment with their causative agents. Fungal disease names may encompass several genera of etiologic agents, consequently being less susceptible to taxonomic changes of the causative species, for example, mucormycosis covers numerous mucormycetous molds.
Racial and Ethnic and Sex Disparities in the Outcomes and Treatment of In‐Hospital Cardiac Arrest: A Nationwide Analysis From the United States
Mohamoud, Abdilahi , Abdallah, N. Ben , Ismayl, Mahmoud , Linzer, Mark , Karim, Rehan, Wardhere, Abdirahman , Goldsweig, Andrew M. , Abdallah, Nadhem , Goldsweig, Andrew M , Ismayl, Mahmoud , Johnson, Dawn

Mayo Clinic

Journal of the American Heart Association | November 11, 2024 | Volume: 14 | Issue: 4 | Pages: No page available

10.1161/jaha.124.038683 | PMID 39526496 Get It

Background In‐hospital cardiac arrest (IHCA) is associated with significant morbidity and mortality. The relationships between race and ethnicity and sex on outcomes and treatment patterns among patients with IHCA remain poorly understood. Methods and Results We conducted a retrospective study using the National (Nationwide) Inpatient Sample (NIS) database from 2016 to 2020 to identify adult patients with IHCA and examine the associations between in‐hospital outcomes and race and ethnicity (White, Black, Hispanic) and sex. The primary outcome was in‐hospital mortality. Secondary outcomes included rates of in‐hospital procedures. Multivariable logistic regression analysis was used to adjust for potential confounders. Among 207 770 patients with IHCA, 26.6% had ventricular tachycardia/ventricular fibrillation and 73.4% had pulseless electrical activity/asystole. For ventricular tachycardia/ventricular fibrillation arrest, Black men (adjusted odds ratio [aOR], 1.42 [95% CI, 1.21–1.66]), Black women (aOR, 1.25 [95% CI, 1.05–1.50]), and Hispanic women (aOR, 1.30 [95% CI, 1.01–1.66]) had higher odds of mortality compared with White men (corresponding adjusted risk ratios [aRRs], 1.10 [CI, 1.06–1.14], 1.06 [95% CI, 1.02–1.11], and 1.08 [95% CI, 1.01–1.14], respectively). In the pulseless electrical activity/asystole arrest subgroup, Black men (aOR, 1.25 [95% CI, 1.11–1.39]) and Hispanic men (aOR, 1.22 [95% CI, 1.07–1.40]) had higher odds of mortality (corresponding aRRs, 1.04 [95% CI, 1.02–1.06] and 1.04 [95% CI, 1.01–1.06], respectively). Black patients with IHCA were less likely to receive percutaneous coronary intervention, coronary artery bypass grafting, and mechanical circulatory support compared with White men. Conclusions Significant racial and ethnic and sex disparities exist in outcomes and treatment patterns among patients with IHCA. Targeted efforts and further studies are needed to better understand and address these disparities and improve outcomes.
Diagnostic performance of deep learning for leg length measurements on radiographs in leg length discrepancy: A systematic review
Lezak, Bradley , Pearle, Andrew D. , Samuelsson, Kristian , Pareek, Ayoosh , Lezak, Bradley A , Samuelsson, Kristian , Pruneski, James A. , Oeding, Jacob F. , Kunze, Kyle N. , Williams, Riley J., Alaia, Erin F. , Dines, Joshua S.

Mayo Clinic

Journal of Experimental Orthopaedics | November 11, 2024 | Volume: 11 | Issue: 4 | Pages: No page available

10.1002/jeo2.70080 | PMID 39530113 Get It

AbstractPurposeTo systematically review the literature regarding machine learning in leg length discrepancy (LLD) and to provide insight into the most relevant manuscripts on this topic in order to highlight the importance and future clinical implications of machine learning in the diagnosis and treatment of LLD.MethodsA systematic electronic search was conducted using PubMed, OVID/Medline and Cochrane libraries in accordance with Preferred Reporting Items for Systematic Review and Meta‐Analysis guidelines. Two observers independently screened the abstracts and titles of potential articles.ResultsA total of six studies were identified in the search. All measurements were calculated using standardized anterior‐posterior long‐leg radiographs. Five (83.3%) of the studies used measurements of the femoral length, tibial length and leg length to assess LLD, whereas one (16.6%) study used the iliac crest height difference to quantify LLD. The deep learning models showed excellent reliability in predicting all length measurements with intraclass correlation coefficients ranging from 0.98 to 1.0 and mean absolute error (MAE) values ranging from 0.11 to 0.45 cm. Three studies reported measurements of LLD, and the convolutional neural network model showed the lowest MAE of 0.13 cm in predicting LLD.ConclusionsMachine learning models are effective and efficient in determining LLD. Implementation of these models may reduce cost, improve efficiency and lead to better overall patient outcomes.Clinical RelevanceThis review highlights the potential of deep learning (DL) algorithms for accurate and reliable measurement of lower limb length and leg length discrepancy (LLD) on long‐leg radiographs. The reported mean absolute error and intraclass correlation coefficient values indicate that the performance of the DL models was comparable to that of radiologists, suggesting that DL‐based assessments could potentially be used to automate the measurement of lower limb length and LLD in clinical practice.Level of EvidenceLevel IV.
Pathologists Providing Direct Patient Care in Thoracic Transplant: Same Objective, Different Scope
Bois, Melanie C. , Aubry, Marie‐Christine, Roden, Anja C. , Meyer, Diane M., Askelson, Rachel K., Praska, Kevin M., Clavell, Alfredo L. , Kennedy, Cassie C. , Scott, John P. , Ameduri, Rebecca , Larson, Nicole L. , Ness, Kelsey L., Gleichner, Kally M., PETERS, K. S., Layman, Andrew J. , Yi, Eunhee S., Maleszewski, Joseph J. , Boland, Jennifer M. , Clavell, Alfredo, Kennedy, Cassie, Ameduri, Rebecca K, Kennedy, Cassie C , Aubry, Marie-Christine, Meyer, Diane M., Praska, Kevin M., Morris, Jonathan M. , Lo, Ying‐Chun , Ness, Kelsey L., Peters, Kristina, Layman, Andrew J. , Yi, Eunhee S.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | November 10, 2024 | Volume: 149 | Issue: 7 | Pages: 673-678

10.5858/arpa.2024-0226-oa | PMID 39522554 Get It

Context.— Cardiac and pulmonary allograft recipients represent a unique population, frequently interacting with support groups and exhibiting intense curiosity about their pathology. Like other solid organ transplant patients, they have enduring and frequent interaction with the laboratory for routine allograft surveillance. Objective.— To address patient requests to understand what happens to their explanted organ and to better understand their disease while simultaneously improving awareness of pathologists’ roles in their continuing care. Design.— At routine follow-up appointments, transplant nurse coordinators offer each allograft recipient the opportunity to interact with a pathologist in our “ On My Path ” program. Organ viewing occurs in a private setting, in a specialized room. Relevant pathology is discussed, and questions are answered, with documentation in the medical record. The patient is subsequently gifted a 3-dimensional model of their explanted organ. Transplant coordinators were surveyed for their feedback on the experience. Results.— One hundred fifty-eight interactions have been documented (2017–2022) at our institution, including patients who underwent cardiac transplant (96, 61%), single or bilateral lung transplant (54, 34%), or combination lung and heart transplant (8, 5%). Transplant coordinators reported an increase in patient understanding of their disease and emotional closure related to the disease through the On My Path program. Conclusions.— Pathologists providing direct patient care is a feasible model that addresses currently unmet desires of the transplant population to better understand their pathology. Providing a 3-dimensional model helps to empower patients and drives satisfaction. These interactions also improve awareness about pathology as a discipline and its importance in the continued care of transplant recipients.
Immune Checkpoint Inhibitor Myopathy
Beecher, Grayson , Pinal‐Fernandez, Iago , Mammen, Andrew L. , Liewluck, T , Pinal-Fernandez, Iago , Beecher, Grayson , Liewluck, Teerin

Mayo Clinic

Neurology | November 8, 2024 | Volume: 103 | Issue: 11 | Pages: No page available

10.1212/wnl.0000000000210031 | PMID 39514829 Get It

ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma
Moertel, Christopher L. , Hirbe, Angela C. , Shuhaiber, Hans, Bielamowicz, Kevin , Sidhu, Alpa , Viskochil, David , Lokku, Armend, Smith, L. Mary, Foreman, Nicholas K. , Hajjar, Fouad, McNall‐Knapp, Rene , Weintraub, Lauren , Antony, Reuben , Franson, Andrea , Schiff, David , Walbert, Tobias , Ambady, Prakash , Bota, Daniela A. , Campen, Cynthia , Kaur, Gurcharanjeet , Maraka, Stefania , Nevel, Kathryn , Aguilar-Bonilla, Ana , Chagnon, Sarah, Dalvi, Nagma , Gupta, Punita , Khatib, Ziad, Metrock, Laura K. , Roberts, Ryan D. , Sadighi, Zsila , Babovic‐Vuksanovic, Dusica , Investigators, for the ReNeu Trial, Raslan, Ahmed M. , Franson, Andrea T., Walter, Andrew , Schiff, David, Hajjar, Fouad M., Slopis, John M. , Klesse, Laura J., Nghiemphu, Leia, Mrugała, Maciej M. , Schmidt, Mary Lou, Foreman, Nick K., Moots, Paul L., Antony, Rueben, Merrell, Ryan , Chagnon, Sarah, Maraka, Stefania, Khatib, Ziad, Foreman, Nicholas K , Franson, Andrea , Meade, Julia , Walbert, Tobias , Klesse, Laura J , Moots, Paul L , Bornhorst, Miriam , Aguilar-Bonilla, Ana , Gupta, Punita , Metrock, Laura K , Nghiemphu, P Leia , Roberts, Ryan D , Babovic-Vuksanovic, Dusica, Gershon, Timothy R , Hirbe, Angela C , Weber, Michael , Klesse, Laura J. , Bornhorst, Miriam , Nghiemphu, Phioanh L. , Robison, Nathan John , Stapleton, Stacie L. , Gershon, Timothy R. , Investigators, for the ReNeu Trial, Franson, Andrea T., Tine, Brian A. Van , Koschmann, Carl , Schiff, David, Hajjar, Fouad M., Capal, Jamie K. , Gill, Jonathan Benjamin , Klesse, Laura J., Kilburn, Lindsay Baker , Foreman, Nick K., Moots, Paul L., Dhamija, Radhika , Antony, Rueben, Chagnon, Sarah, Maraka, Stefania, Khatib, Ziad

Mayo Clinic

Journal of Clinical Oncology | November 8, 2024 | Volume: 43 | Issue: 6 | Pages: 716-729

10.1200/jco.24.01034 | PMID 39514826 Get It

PURPOSE Pharmacologic therapies for neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PNs) are limited; currently, none are US Food and Drug Administration–approved for adults. METHODS ReNeu is an open-label, multicenter, pivotal, phase IIb trial of mirdametinib in 58 adults (≥18 years of age) and 56 children (2 to 17 years of age) with NF1-PN causing significant morbidities. Patients received mirdametinib capsules or tablets for oral suspension (2 mg/m 2 twice daily, maximum 4 mg twice daily), regardless of food intake, in 3 weeks on/1 week off 28-day cycles. The primary end point was confirmed objective response rate (ORR; proportion of patients with a ≥20% reduction of target PN volume from baseline on consecutive scans during the 24-cycle treatment phase) assessed by blinded independent central review (BICR) of volumetric magnetic resonance imaging. RESULTS Twenty-four of 58 adults (41%) and 29 of 56 children (52%) had a BICR-confirmed objective response during the 24-cycle treatment phase; in addition, two adults and one child had confirmed responses during long-term follow-up. Median (range) target PN volumetric best response was –41% (−90 to 13) in adults and –42% (−91 to 48) in children. Both cohorts reported significant and clinically meaningful improvement in patient- or parent proxy-reported outcome measures of worst tumor pain severity, pain interference, and health-related quality of life (HRQOL) that began early and were sustained during treatment. The most commonly reported treatment-related adverse events were dermatitis acneiform, diarrhea, and nausea in adults and dermatitis acneiform, diarrhea, and paronychia in children. CONCLUSION In ReNeu, the largest multicenter NF1-PN trial reported to date, mirdametinib treatment demonstrated significant confirmed ORRs by BICR, deep and durable PN volume reductions, and early, sustained, and clinically meaningful improvement in pain and HRQOL. Mirdametinib was well-tolerated in adults and children.